Role of interleukin (IL)-17 and T-helper (Th)17 cells in cancer

• IL-17 have been found to exert a pro- or anti-tumourigenic effect in cancer.
• Th17 cells are related to other IL-17-Producing Cells.
• Th17-associated cytokines in tumor give impetus to tumor progression, or inducing angiogenesis and metastasis.
• The balance between Th17 cells and Treg cells play the effective role in tumor Context as well as Th17/Th1 plasticity.

Interleukin-17 (IL-17), a pleiotropic proinflammatory cytokine, is reported to be significantly generated by a distinct subset of CD4+ T-cells, upgrading cancer-elicited inflammation and preventing cancer cells from immune surveillance. T-helper (Th)17 cells produced from naive CD4+ T cells have recently been renowned and generally accepted, gaining eminence in cancer studies and playing the effective role in context of cancer. Th17 cells are the main source of IL-17-secreting cells, It was found that other cell types produced this cytokine as well, including Group 3 innate lymphoid cells (ILC3), δγT cells, invariant natural killer T (iNKT) cells, lymphoid-tissue inducer (LTi)-like cells and Natural killer (NK) cells. Th17-associated cytokines give impetus to tumor progression, or inducing angiogenesis and metastasis. This review demonstrates an understanding on how the pro- or antitumor function of Th17 cells and IL-17 may change cancer progression, leading to the appearance of complex and pivotal biologic activities in tumor.